Examining muscle relaxant dose, risk of encephalopathy in patients with CKD

What The Study Did: Whether a higher or lower dose of the muscle relaxant baclofen was associated with 30-day risk of hospitalization with encephalopathy (defined as a main diagnosis of delirium, disorientation, transient alteration of awareness, transient ischemic attack or an unclear diagnosis of dementia) among newly prescribed patients with chronic kidney disease was the focus of this observational study with nearly 16,000 older adults.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

Authors: Flory T. Muanda, M.D., Ph.D., of the Institute for Clinical Evaluative Sciences in London, Ontario, Canada, is the corresponding author.

(doi:10.1001/jama.2019.17725)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Media advisory: The full study is linked to this news release. This study is being released to coincide with presentation at Kidney Week 2019.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.17725?guestAccessKey=da673453-54aa-42c7-9b1b-9e0c082c57d9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110919

Media Contact
JAMA Network Media Relations

[email protected]

Comments